Bioheart Announces University of Miami as Clinical Site for ANGEL Trial of LipiCell(TM) Bioheart, Inc. announced that the company will conduct the ANGEL trial using adipose derived stem cell technology or LipiCell(TM) at the University of Miami Miller School of Medicine. [MarketWatch] Press Release VistaGen Therapeutics and Duke University Enter Into Strategic Research Collaboration VistaGen Therapeutics, Inc. and Duke University have entered into a strategic research collaboration aimed at combining their complementary expertise at the forefront of cardiac stem cell technology, electrophysiology and tissue engineering. The initial goal of the collaboration is to explore potential development of novel, engineered, stem cell-derived cardiac tissues to expand the scope of VistaGen’s drug rescue capabilities focused on heart toxicity. [VistaGen Therapeutics, Inc.] Press Release Arrowhead Research Corporation and Axolabs GmbH Enter into Strategic Alliance and Master Services Agreement for RNAi Therapeutics Arrowhead Research Corporation and Axolabs GmbH announced that they have entered into a Strategic Alliance and Master Services Agreement. Under the terms of the agreement, Axolabs will provide Arrowhead and its partners first-in-class oligonucleotide optimization, synthesis, and analytics. [Arrowhead Research Corporation] Press Release Artificial Liver Cells Win Their Creator Prize for Their Potential to Reduce Animal Experiments Producing liver cells that demonstrate inherited liver diseases from human skin cells has earned Dr Ludovic Vallier from the University of Cambridge a major prize from the National Centre for the Replacement, Refinement and Reduction of Animals in Research. [University of Cambridge] Press Release QF Awards Top Stem Cell Researchers at International Conference Research on preventing breast cancer recurrence, using organ regeneration to combat obesity-related diseases, and enabling vascular repair for patients suffering from cardiovascular disease received awards at the Qatar International Conference on Stem Cell Science and Policy 2012. [Qatar Foundation (QF)] Press Release
Clinical Development Program Receives FDA “Fast Track Designation” and Encouraging Phase Ib Safety Results for Viaskin Peanut DBV Technologies announced that it has received “Fast Track Designation” for the Clinical Development Program of its Viaskin® Peanut, a product designed for the treatment by Epicutaneous Immunotherapy of patients with peanut allergy. [DBV Technologies] Press Release Arrowhead Announces Patent Issuance Covering siRNA Inhibitors of HIF-2a (EPAS1) Arrowhead Research Corporation announced that the United States Patent and Trademark Office has issued U.S. Patent No. US 8,114,983 B2 entitled, “Compositions and use of EPAS1 inhibitors.” Included in the patent are claims directed to siRNA sequences targeting the hypoxia-inducible factor 2 alpha gene (HIF-2a) or endothelial PAS domain protein 1 (EPAS1), chemical modifications which enhance stability and/or biological activity, compositions, methods, and uses. [Arrowhead Research Corporation] Press Release LCT Granted E.U. Patent for Tissue Engineering Living Cell Technologies Limited (LCT) received formal notification that it has been granted E.U. Patent No. 1,438,395 from the European Patent Office. The patent protects the ability to culture two different types of cells derived from Auckland Island pigs, therefore enabling the assembly and maintenance of a mix of cells or artificial tissue in culture for xenotransplantation therapies. [Living Cell Technologies Limited] Press Release Alnylam and the University of Massachusetts Medical School Announce Tuschl I Patent Upheld in European Opposition Proceedings Alnylam Pharmaceuticals, Inc. and the University of Massachusetts Medical School reported that the European Patent Office has upheld the Tuschl I ’726 patent in oral opposition proceedings held in Munich, Germany. [Alnylam Pharmaceuticals, Inc.] Press Release Tekmira Expands Product Pipeline with RNAi Therapeutic for the Treatment of Alcohol Dependence Tekmira Pharmaceuticals Corporation announced that it is adding a new RNAi therapeutic targeting ALDH2 for the treatment of alcohol dependence to its product pipeline. [Tekmira Pharmaceuticals Corporation] Press Release Galena Biopharma Announces Expansion of Scientific Advisory Board Galena Biopharma announced the appointment of David A. Scheinberg, M.D., Ph.D. to the Company’s Scientific Advisory Board. [Galena Biopharma] Press Release International Cell Medicine Society Elects New President The International Cellular Medicine Society (ICMS) announces that Dr Ricardo Rodriguez, MD has been elected President of the ICMS Board of Directors. [International Cellular Medicine Society] Press Release |